Overview of the Market:
North America Monoclonal Antibodies Market is estimated to be a USD 9.63 billion market in 2018 and is expected to reach USD 16.81 billion market by the end of 2023 with a significant growth rate of 10.5%. Cancer is the leading cause of death currently across the globe. It starts with a single cell genetically transforming normal cell into tumour and is spread gradually to the other cells. The dramatic increases in the number of cancer cases has prompted many pharmaceutical companies to invest in monoclonal antibodies. The practise for curing cancer currently include usage of drugs and chemotherapy which have adverse side effects. This persuade the usage of Monoclonal antibodies.
Recent years have seen the emergence of monoclonal antibodies market, offering less toxic and highly efficient therapeutics alternatives. The antibody agents are used to cure a wide array of diseases, especially cancer, autoimmune and inflammatory diseases. They are mono-specific antibodies having identical immune cells that are clone to the single parent cells and are directed to a specific target cell. This customizable feature of the antibodies due to its specific nature can play a critical role in eliminating the cancer cell while sparing the healthy cells. Monoclonal antibodies are more effective in treating cancer than their counter parts like drugs or chemotherapy owing to their adverse side effects.
The drastic increase in the people affected by cancer prompted many pharmaceutical firms to invest in monoclonal antibodies. Rise in investment in R&D of genomic studies, technological innovations in target gene selection and genetic sequencing, monoclonal antibodies ability to target only specific cells, having no side effects compared to its counter parts are the primary drivers for the market. With the increased occurrence of cancer, the market is expected to grow significantly in the next 5 years having a presence of highly strong products in the pipeline. There are also few restraints for its market entry like high cost, stringent guidelines, long durations required for R&D, clinical trials.
Geographical Analysis:
The North America Monoclonal Antibodies are categorised on the basis of application as Breast, Brain, blood, Liver, Hodgkins and Non-Hodgkins lymphoma, leukaemia, colorectal and others. The market is again segmented based on type as chimeric and humanised antibodies, murine antibodies and fully humanized antibodies. The market is again divided into various categories by conjugated cancer therapies as Radoimmunotherapy, ADEPT, Immunoliposome, immunocytokines and others. Based on the geographical region of North America it is segmented into US and Canada.
Key Players in this Market:
The major companies in this industry are Amgen, Genmab, Briston Myers squibb, glaxosmithkline, Eli Lilly, Roche, Immunogen, Seattle Genetics, Novartis and Spectrum Pharmaceuticals.
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5.1 By Application
5.1.1 Liver
5.1.2 Breast
5.1.3 Brain
5.1.4 Blood
5.1.5 Hodgkins and Non-Hodgkins lymphoma
5.1.6 Colorectal
5.1.7 Leukaemia
5.1.8 Others
5.2 By Type
5.2.1 Murine Antibodies
5.2.2 Chimeric and Humanised Antibodies
5.2.3 Fully Humanized Antibodies
5.3 Conjugate Cancer Therapies
5.3.1 Immunoliposome
5.3.2 Radioimmunotherapy
5.3.3 ADEPT
5.3.4 Immunocytokines
5.3.5 Others
6.1 Introduction
6.2 United States
6.3 Canada
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.1 Roche
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Amgen
8.3 Genmab
8.4 Glaxosmithkline
8.5 Bristol Meyer Squibb
8.6 Eli Lilly
8.7 Immunogen
8.8 Novartis
8.9 Seattle Genetics
8.10 Spectrum Pharmaceuticals
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
